Bicyclomycin benzoate, an antibiotic, exhibits activity against a broad spectrum of Gram-negative/Gram-positive bacteria.

Bicyclomycin interferes with the biosynthesis of lipoprotein and its assembly to peptidoglycan in the cell envelope of E. coli. At the lethal level, Bicyclomycin is shown to inhibit the synthesis of RNA and protein in the growing cells of E. coli 15 THU [1]. Bicyclomycin targets the rho transcription termination factor in Escherichia coli. Bicyclomycin can disrupt the rho molecular machinery thereby leading to a catastrophic effect caused by the untimely overproduction of proteins not normally expressed constitutively, thus leading to a toxic effect on the cells [2]. The inhibition of rho poly(C)-stimulated hydrolysis of ATP by Bicyclomycin has been found to proceed by a non-competitive, reversible pathway with respect to ATP (Ki: 20 μM) [3].

Following a single intramuscular administration of Bicyclomycin at a dosage of 50 mg/kg in rats, the compound exhibits a low rate of excretion. It is well distributed across different tissues, with the peak concentration recorded in the kidneys at a level of 100 mg/kg [4].